منابع مشابه
Case-Based Review: newly diagnosed glioblastoma
Department of Neurology and Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota (D.R.J.); Department of Radiation Oncology, University of California, San Francisco, California (S.E.F.); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (C.G., A.R.); Department of Radiology, Mayo Clinic, Rochester, Minnesota (T.J.K.); Department of Neurological Surger...
متن کاملROLe Of beVacizumab iN NewLy diagNOsed gLiObLastOma
Chemoradiation (CRT) with temozolomide (TMZ/CRT+TMZ) is the standard of care for newly diagnosed glioblastoma (GBM). This phase III trial, conducted by the Radiation Therapy Oncology Group (RTOG), North Central Cancer Treatment Group (NCCTG) and Eastern Cooperative Oncology Group (ECOG), evaluated whether adding bevacizumab (Bev) to standard CRT improves overall survival (OS) or progression-fre...
متن کاملA randomized trial of bevacizumab for newly diagnosed glioblastoma
Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagno...
متن کاملA randomized trial of bevacizumab for newly diagnosed glioblastoma.
BACKGROUND Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with n...
متن کاملAdvances in the treatment of newly diagnosed glioblastoma
Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a new generation of personalized clinical trials. Using ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Oncology
سال: 2021
ISSN: 2234-943X
DOI: 10.3389/fonc.2020.574012